SCHEMBL2118988

SCHEMBL2118988

Cc1cc(S(=O)(=O)Nc2cc(-c3ccco3)ccc2C)ccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 3/20 0.56
CKS1B P61024 1/20 0.44
SKP2 Q13309 1/20 0.44
CYP3A4 P08684 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
ALOX15 P16050 1/20 0.42
ALDH1A1 P00352 4/20 0.41
HPGD P15428 3/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HSP90AA1 P07900 1/20 0.41
POLB P06746 2/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 1/20 0.41
CYP2D6 P10635 2/20 0.40
PSEN1 P49768 2/20 0.40
PSEN2 P49810 2/20 0.40
APH1B Q8WW43 2/20 0.40
NCSTN Q92542 2/20 0.40
APH1A Q96BI3 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117223 0.88 TRIM24 (0.55) TRIM24CKS1BSKP2CYP3A4SMN1; SMN2
SCHEMBL2117095 0.87 TRIM24 (0.52) TRIM24CKS1BSKP2CYP3A4SMN1; SMN2
SCHEMBL2119290 0.87 TRIM24 (0.55) TRIM24CKS1BSKP2CYP3A4SMN1; SMN2
SCHEMBL2119449 0.85 CYP3A4 (0.46) TRIM24CYP3A4SMN1; SMN2ALDH1A1HPGD
SCHEMBL2121409 0.85 TRIM24 (0.55) TRIM24CKS1BSKP2CYP3A4SMN1; SMN2
SCHEMBL2117486 0.84 POLB (0.43) TRIM24CYP3A4SMN1; SMN2ALOX15ALDH1A1
SCHEMBL2119450 0.83 TRIM24 (0.52) TRIM24CKS1BSKP2CYP3A4SMN1; SMN2
SCHEMBL2120627 0.82 TRIM24 (0.59) TRIM24CYP3A4SMN1; SMN2ALOX15ALDH1A1
SCHEMBL2118125 0.81 TRIM24 (0.48) TRIM24CKS1BSKP2CYP3A4ALDH1A1
SCHEMBL2120619 0.81 TRIM24 (0.57) TRIM24CKS1BSKP2CYP3A4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 TRIM24 2142/4885CKS1B 268/4885SKP2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.